CC
MYGN icon

Chase Coleman’s Myriad Genetics MYGN Stock Holding History

Chase Coleman’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-291,097
Closed -$10.3M – 48
2015
Q1 		$10.3M Sell
291,097
-1,608,903
-85% -$57.6M 0.11% 43
2014
Q4 		$64.7M Hold
1,900,000
– – 0.76% 31
2014
Q3 		$73.3M Hold
1,900,000
– – 0.97% 22
2014
Q2 		$73.9M Sell
1,900,000
-445,921
-19% -$16.6M 0.94% 24
2014
Q1 		$80.2M Buy
2,345,921
+1,143,821
+95% +$35.4M 1.09% 23
2013
Q4 		$25.2M Buy
+1,202,100
New +$30.4M 0.31% 44

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Chase Coleman's MYGN Position: Q2 2015 in Review

Chase Coleman sold out of Myriad Genetics (MYGN) in Q2 2015, closing a stake of 291,097 shares — an estimated $10.3M sold.

Chase Coleman first reported a position in MYGN in Q4 2013 and held it in 6 quarters. The position peaked at $80.2M in Q1 2014. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2015.

  • Chase Coleman reported no remaining Myriad Genetics position as of Q2 2015 after selling out during the quarter.
  • Chase Coleman sold 291,097 Myriad Genetics shares in Q2 2015, an estimated $10.3M.
  • Chase Coleman first reported a position in Myriad Genetics in Q4 2013 and held it in 6 quarters.
  • Chase Coleman's Myriad Genetics position peaked at $80.2M in Q1 2014.
  • 235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2015.

Based on Tiger Global Management's 13F filing for Q2 2015, filed 14 Aug 2015.